- A gross income of $250,000 or more per annum in each of the previous two financial years; or
- Net assets of at least $2.5 million; and
- A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)
Prescient Therapeutics – Interview with Dr Allen Ebens
In the battle against blood cancer, chimeric antigen receptor T cell (CAR-T) therapy is proving...
How CAR-T uses the body’s own immune system to fight cancer
Special Report: A form of immunotherapy that involves modifying a patient’s white blood cells so...
Shedding Light on Prescient Therapeutics’ (PTX) Personalised Cancer Treatments
Today, we will acquaint you with the product pipeline of ASX-listed clinical-stage biotechnology company Prescient Therapeutics...
ASX small caps leading the fight against cancer
StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each...
From the garage to a COVID-19 vaccine lab
When local synthetic antibiotics developer Recce Pharmaceuticals announced they had entered into an antiviral Sars-CoV-2...
Prescient Therapeutics raises $7 million to fund cancer treatment pipeline
Biotech Prescient Therapeutics (ASX: PTX) has successfully raised $7 million to fund an expanded pipeline...
Health Kick Podcast: Chemo’s diminishing role, the ‘personalised’ approach to cancer treatment and PTX’s CAR-T innovations
Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the pen and picking...
Prescient Therapeutics is developing novel personalised therapies against a range of cancers – Small Caps
Prescient Therapeutics (ASX: PTX) Chief Executive Officer Steven Yatomi-Clarke joins Small Caps to discuss the...
Local small cap is developing next gen cancer therapies
Locally-listed small cap biotech company Prescient Therapeutics hopes to shift the conversation around cancer from treatments to...